This website uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Statement for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time. I accept / More info
For more information on which cookies we use then please refer to our Cookie Policy.
Setting up the KWM International Center is a significant strategic deployment for the firm.
King & Wood Mallesons’ cross-border team, advised Luye Pharma Hong Kong Limited (“Luye Pharma”) on its transaction signed with AstraZeneca relating...
Analysis of the 2018-19 Australian Federal Budget: significant reforms for corporates, small business and personal tax.
King & Wood Mallesons (KWM) was the biggest winner with 12 awards at the Thomson Reuters ALB China Law Awards 2018 held in Beijing.
We explore how international arbitration has adapted and will continue to adapt in 2018 to global challenges and opportunities.
King & Wood Mallesons has improved its overall position in the 2017 Acritas Global Elite Law Firm Brand Index, ranking 13th.
Implication of the Blocked Lattice/Canyon Bridge Transaction of Future CFIUS Filing by Chinese Investors.
Government supervision of medical institutions has become increasingly stringent.
King & Wood Mallesons appoints its first EUME Managing Partner, and continues to strengthen the team by welcoming new partners